41.76
-0.39(-0.93%)
Currency In USD
Address
8000 Marina Boulevard
Brisbane, CA 94005
United States of America
Phone
650 770 0077
Website
Sector
Healthcare
Industry
Biotechnology
Employees
152
First IPO Date
May 14, 2021
| Name | Title | Pay | Year Born |
| Marshall Fordyce | Founder, President, Chief Executive Officer & Director | 1.03M | 1974 |
| Jason S Carter | Chief Legal Officer | 256,700 | 1976 |
| Allen Ebens | Executive Vice President of Research | 397,024 | N/A |
| Sean Grant | Chief Financial Officer | 642,000 | 1984 |
| Robert Brenner | Chief Medical Officer | 828,753 | 1968 |
| David L. Johnson | Chief Opearating Officer | 0 | 1970 |
| Joseph R. Young | Senior VP of Finance & Chief Accounting Officer | 0 | 1972 |
| Debra Charlesworth | Vice President of Corporate Communications | 0 | N/A |
| Emma Haywood | Vice President of Marketing | 0 | N/A |
| S. Sandra Park | Senior Vice President of Legal, Healthcare,Commercial Law, Compliance & Operations | 0 | N/A |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.